A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients

Antivir Ther. 2005;10(2):277-84.

Abstract

Changes in the hepatitis C virus (HCV) viral load (VL) were assessed in a retrospective study of 50 HIV/HCV-coinfected patients who initiated highly active antiretroviral therapy (HAART). Most patients responded to HAART [during the first 6 months, plasma HIV VL fell by a mean 1.39 log10, becoming undetectable (<400 copies/ml) in 22% and CD4+ T cells increased by a mean of 100 cells/microl], but surprisingly, 27 (54%) showed some rise and 25 (50%) showed a significant increase in the HCV VL. This figure was considered to be a minimum estimate. A majority of the patients showed an increase of less than 1 log10 that was associated with a rapid decrease in the HIV VL, whereas an increase in the HCV VL of greater than 1 log10, noted in eight patients, was associated with a baseline CD4+ cell count of less than 200 cells/microl. The increase in the HCV VL was not associated with hepatitis as determined by raised alanine transferase.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Australia
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • Hepacivirus / isolation & purification*
  • Hepatitis C / complications
  • Hepatitis C / virology*
  • Humans
  • Male
  • Protease Inhibitors / therapeutic use*
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Time Factors
  • Viral Load

Substances

  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors